Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Regulation

FDA

Vitruvias Recalls Lot of Thyroid Tablets Over 'Superpotent' Test Results

Testing showed Lot 504950 may deliver excess thyroid hormone, so the company has withdrawn the batch and is notifying distributors for destruction.

Manufacturer Recalls Generic Zyrtec Over Possible Ranitidine Contamination

FDA Names Mike Davis Acting Drug Chief as Tracy Beth Høeg Exits

FDA Proposes Blocking Bulk Compounding of GLP-1 Drugs by Outsourcing Facilities

ImmunityBio Files FDA Response on Anktiva Ads as Investor Suits Build

FDA Warns ImmunityBio Over Anktiva Ads, Citing Misleading Cancer Claims

FDA Biologics Chief Vinay Prasad to Step Down at End of April

FDA Installs Tracy Beth Hoeg as Acting CDER Director as Pazdur Files Retirement

FDA Names Richard Pazdur to Lead Drug Review Center

FDA to Remove Most Boxed Warnings From Menopause Hormone Therapies

FDA Class II Recall Targets 580,000 Prazosin Bottles for Nitrosamine Overages

FDA Posts More Than 100 Warning Letters in Drug Ad Crackdown, Targeting Hims, Lilly and Novo

Sarepta Temporarily Halts Elevidys Shipments Under FDA Request

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research